JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

JNJ

238.23

-0.2%↓

UNH

273.19

-0.82%↓

TMO

539.43

-1.35%↓

ABT

112.32

+1.08%↑

ISRG

495.1

+0.46%↑

Search

Baxter International Inc

Chiusa

SettoreSettore sanitario

21.95 0.97

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.62

Massimo

22.33

Metriche Chiave

By Trading Economics

Entrata

-173M

-51M

Vendite

25M

2.8B

P/E

Media del settore

86.308

84.243

Rendimento da dividendi

3.39

Margine di Profitto

-1.799

Dipendenti

38,000

EBITDA

-46M

416M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.89% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.39%

2.28%

Utili prossimi

12 feb 2026

Prossima data del Dividendo

31 mar 2026

Prossima data del' Ex Dividendo

27 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.7B

10B

Apertura precedente

20.98

Chiusura precedente

21.95

Notizie sul Sentiment di mercato

By Acuity

57%

43%

280 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Baxter International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 feb 2026, 23:26 UTC

I principali Market Mover

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb 2026, 22:31 UTC

Utili

Correction to America Movil 4Q Profit Article

10 feb 2026, 22:22 UTC

Utili

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb 2026, 23:51 UTC

Discorsi di Mercato
Utili

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb 2026, 23:42 UTC

Discorsi di Mercato

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb 2026, 23:40 UTC

Discorsi di Mercato
Utili

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb 2026, 23:21 UTC

Discorsi di Mercato

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb 2026, 23:21 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

10 feb 2026, 22:17 UTC

Discorsi di Mercato

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb 2026, 22:15 UTC

Utili

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb 2026, 22:10 UTC

Utili

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb 2026, 22:10 UTC

Utili

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb 2026, 22:09 UTC

Utili

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb 2026, 22:09 UTC

Utili

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb 2026, 22:01 UTC

Utili

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb 2026, 21:54 UTC

Utili

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb 2026, 21:53 UTC

Utili

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb 2026, 21:51 UTC

Utili

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb 2026, 21:51 UTC

Utili

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:51 UTC

Utili

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb 2026, 21:51 UTC

Utili

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb 2026, 21:51 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb 2026, 21:50 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb 2026, 21:50 UTC

Utili

James Hardie Industries 3Q EPS 12c >JHX

10 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

10 feb 2026, 21:50 UTC

Utili

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb 2026, 21:49 UTC

Utili

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb 2026, 21:49 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb 2026, 21:48 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb 2026, 21:47 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Confronto tra pari

Modifica del prezzo

Baxter International Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.89% in crescita

Previsioni per 12 mesi

Media 22.14 USD  1.89%

Alto 30 USD

Basso 15 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Baxter International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

7 ratings

2

Acquista

4

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

30.475 / 31.345Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

280 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat